Nasdaq rxrx
With Recursion Pharmaceuticals stock trading at $11.93 per share, the total value of Recursion Pharmaceuticals stock (market capitalization) is $2.58B. Recursion Pharmaceuticals stock was originally listed at a price of $31.30 in Apr 16, 2021. If you had invested in Recursion Pharmaceuticals stock at $31.30, your return over the last 2 years ...Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing ...Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd …
Did you know?
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues. Simply Wall St. Published December 09, 2023. Source: …SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two ...Clinical-stage biotech company Recursion Pharmaceuticals (NASDAQ:RXRX) might be a relatively small company, but it’s taking significant steps toward a stronger future. Wall Street currently ...Welcome to Recursion: The Future of TechBio. LEARN HOW ›. NEWS: Recursion unveils LOWE, an LLM-Orchestrated Workflow Engine for drug discovery. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company.
Aug 11, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (-2.63%) -$0.26 ... When it comes to complex biotech stocks like Recursion Pharmaceuticals (RXRX-2.63%), skilled investors ... Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues Dec 09. Co-Founder notifies of intention to sell stock Dec 08. Chief Financial Officer exercised options and sold US$266k worth of stock Nov 19. Consensus EPS estimates fall by 18% Nov 16.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past yearRXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Sep 14, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week. This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and artificial ... NVIDIA Corporation Common Stock. $450.47 +0.42 +0.09%. MSFT. Microsoft Corporation Common Stock. $352.60 -0.20 -0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours ...Health Care Sector Update for 01/04/2024: SEM, XERS, RXRX, OMGA, NVO January 04, 2024 — 03:53 pm EST Written by MT Newswires for MTNewswires ->…
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Twist Bioscience (NASDAQ: TWST), like RXRX, is a genomics stock pos. Possible cause: Find the latest news headlines from Recurs...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past yearGet the latest updates on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) after hours trades, after hours share volumes, and more. Make informed investments with Nasdaq.
Dec 22, 2023 · The NASDAQ 100 After Hours Indicator is down -8.22 to 16,769.18. The total After hours volume is currently 64,637,594 shares traded.The following are the most active stocks for the after hours ... Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year
ar 12 magazine Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is the latest addition in Srini Akkaraju and Michael Dybbs’ hedge fund portfolio, as Samsara BioCapital bought 775,583 shares worth $28.31 million ... turkce altyazili poornordk 10000 Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... boss industrial 27 ton horizontal and vertical gas log splitter Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago.Institutional investors have sold a total of 19,621,281 shares in the last 24 months. This volume of shares sold represents approximately $160.50M in transactions. Related Companies: ImmunityBio Institutional Ownership. Neumora Therapeutics Institutional Ownership. This page (NASDAQ:RXRX) was last updated on 1/15/2024 … freie trauerfeiernanime viet subobxlyxtj The NASDAQ 100 After Hours Indicator is down -8.22 to 16,769.18. The total After hours volume is currently 64,637,594 shares traded.The following are the most active stocks for the after hours ...In recent news, Recursion (NASDAQ: RXRX), a prominent clinical stage TechBio firm, has announced the signing of agreements to acquire Cyclica and Valence, two companies with expertise in AI-enabled drug discovery.These acquisitions strengthen Recursion's position in computational chemistry, machine learning, and artificial … gmbh report RECURSION PHARMACEUTICALS INC ( RXRX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 43% based on the firm’s underlying fundamentals and the ... followupboss.comgeorge washington 2023 2024 sdneso can Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States.